Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT05898477
Status
Recruiting
Apply to this trial

Conditions

  • Hemophagocytic Lymphohistiocytoses
  • Lymphoma

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.

Key Dates

Start date
May 1, 2023
Status verified
Jan 2026
Primary completion
Jan 31, 2028
Completion
Jul 31, 2028

Study Design

Enrollment
2,000 participants (estimated)

Arms

  • Arm: Hemophagocytic lymphohistiocytosis (HLH) Patients

Primary Outcome Measure

To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+ [ Time Frame: The participant's survival would be assessed at 180 days from the malignancy diagnosis ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35294
Gaurav Goyal, MD
[email protected]
2059346770

Find similar trials in Birmingham, AL

By research site
University of Alabama at Birmingham· Birmingham, AL

Related Studies